Approved indications (U.S.):

• Adults with unresectable locally advanced or metastatic triple‑negative breast cancer (mTNBC) who have received at least two prior systemic therapies, including one for metastatic disease.
• Adults with unresectable locally advanced or metastatic hormone receptor–positive, HER2‑negative (HR+/HER2‑) breast cancer who have received endocrine‑based therapy and at least two additional systemic therapies in the metastatic setting.

Off‑label and investigational use: Trodelvy is being studied in other cancers such as non‑small cell and small cell lung cancer, head and neck cancers, gynecologic cancers, and additional breast and urothelial cancer settings; outside of clinical trials, off‑label use is generally reserved for select patients at experienced centers when alternatives are limited and evidence is still emerging.

Efficacy in metastatic triple‑negative breast cancer:

• In heavily pretreated mTNBC, Trodelvy substantially improved outcomes versus single‑agent chemotherapy, roughly tripling tumor response rates (about one‑third of patients vs about 1 in 20 on standard chemo).
• It significantly prolonged progression‑free survival (disease control lasting around 5–6 months vs about 2 months) and overall survival (around 11–12 months vs about 7 months on average), with some patients benefiting for a year or longer.
• Responses are usually assessed by scans after 2–3 treatment cycles (about 6–9 weeks), though symptom relief such as less pain or improved energy may appear earlier.

Efficacy in HR+/HER2‑ metastatic breast cancer:

• In patients whose cancer progressed after endocrine therapy and multiple chemotherapies, Trodelvy delayed cancer growth compared with standard chemotherapies and modestly increased the chance of tumor shrinkage.
• It extended overall survival by roughly 3 additional months on average versus chemotherapy and improved quality‑of‑life measures like fatigue and global health status.

Comparison with other drugs: Compared with traditional single‑agent chemotherapies used late in metastatic breast cancer, Trodelvy generally offers higher response rates and longer disease control and survival, at the cost of more frequent low white blood cell counts and diarrhea, but with a safety profile that is predictable and manageable in most patients under close monitoring.

Typical dosing and how it is given:

• The usual adult dose is 10 mg per kg of body weight, given by intravenous (IV) infusion on Days 1 and 8 of a 21‑day (3‑week) cycle.
• The first infusion is typically given over about 3 hours; if well tolerated, later infusions may be shortened to about 1–2 hours.
• Trodelvy is given only as an IV infusion in a clinic or infusion center; it is not taken by mouth and is not given as a quick IV push.
• Before each dose, patients usually receive premedications (such as anti‑nausea drugs and medicines to prevent infusion reactions), and blood tests are checked to be sure counts and organ function are acceptable.
• Treatment continues as long as the cancer is controlled and side effects remain manageable, with dose reductions (for example, to 7.5 mg/kg or 5 mg/kg) or delays if needed.

Special dosing instructions:

• Trodelvy should not be substituted for or used together with other drugs containing irinotecan or SN‑38.
• People at higher risk of neutropenia (such as those with prior severe low counts or certain UGT1A1 variants) may receive preventive growth‑factor injections (G‑CSF) and may need earlier dose reductions.
• Use in people with moderate or severe liver impairment is generally avoided or approached very cautiously, with individualized decisions by the oncology team.
• There are no routine food restrictions, but maintaining good hydration and promptly treating diarrhea are important.

Missed doses:

• If an infusion appointment is missed or lab results delay treatment, patients should contact their oncology team as soon as possible; the schedule and future doses will be adjusted by the care team, and patients should not attempt to “double up” or change the timing on their own.

Overdose:

• There is no specific antidote for Trodelvy overdose; management focuses on close monitoring and treatment of expected toxicities such as severe neutropenia, infections, and diarrhea, often in a hospital setting.
• Any suspected overdose or administration error should be reported immediately to the treating oncology team so that monitoring and supportive care can begin without delay.

Common side effects (often during the first few cycles):

• Gastrointestinal: Nausea, diarrhea, vomiting, constipation, and abdominal pain are very common; most are mild to moderate but diarrhea and nausea can be severe and usually begin within days after infusion, so preventive anti‑nausea medicines and early use of anti‑diarrheal drugs are important.
• Blood counts: Low white blood cell counts (especially neutropenia), anemia, and less often low platelets occur frequently; these may cause fatigue, increased risk of infections, or shortness of breath and are monitored with regular blood tests.
• General and other: Fatigue or weakness, hair loss, decreased appetite, mouth sores, and infections (such as respiratory or urinary infections) are common; many patients need dose delays or reductions over time.

Serious or rare adverse effects needing urgent attention:

• Severe neutropenia and infection (boxed warning): Fever, chills, sore throat, cough, shortness of breath, burning with urination, or any signs of infection can signal dangerously low white blood cells and require immediate medical evaluation.
• Severe diarrhea (boxed warning): Frequent loose stools, diarrhea that starts suddenly, blood in the stool, or diarrhea with dizziness, lightheadedness, or reduced urination can quickly lead to dehydration and kidney problems and should be reported at once.
• Allergic and infusion reactions: Swelling of the face or throat, hives, rash, itching, flushing, chest tightness, trouble breathing, wheezing, dizziness, or fainting during or within 24 hours of infusion may indicate a serious reaction; infusions may need to be slowed, stopped, or the drug discontinued.
• Other serious problems: Rarely, severe lung inflammation, severe abdominal pain from colitis or neutropenic colitis, blood clots, or heart rhythm problems can occur and require urgent assessment.

Warnings and precautions:

• Pregnancy and fertility: Trodelvy can seriously harm an unborn baby; effective contraception is recommended during treatment and for 6 months after the last dose for females who can become pregnant, and for 3 months after the last dose for males with partners who can become pregnant. It may reduce fertility in females.
• Breastfeeding: Breastfeeding is not recommended during treatment and for 1 month after the last dose.
• Liver function: Trodelvy has not been well studied in moderate or severe liver impairment, and caution or alternative treatments may be needed; even with mild liver problems, close monitoring of liver tests is typical.
• UGT1A1*28 genotype and prior irinotecan toxicity: People with reduced UGT1A1 activity (for example, those who carry UGT1A1*28) or those who had severe neutropenia or diarrhea with irinotecan are at higher risk for these toxicities and may need closer monitoring, earlier dose reductions, or preventive growth‑factor support.
• Children and older adults: Safety in children is unknown; in older adults, side effects are broadly similar but may be more difficult to tolerate, so dose adjustments and closer monitoring are often used.

Overall safety profile: Trodelvy’s side effects are similar to intensive chemotherapy (notably neutropenia, diarrhea, nausea, fatigue, and hair loss), but because it is targeted to Trop‑2, many patients can stay on treatment longer than with some standard chemotherapies when side effects are proactively managed.

Reporting side effects and safety updates: In the United States, side effects can be reported to the FDA MedWatch program or to the manufacturer, and updated safety information is available from the FDA and Trodelvy’s official prescribing information and patient website.

Interactions with other medicines:

• UGT1A1 inhibitors: Drugs that strongly inhibit the UGT1A1 enzyme (used to clear SN‑38) can raise Trodelvy’s active drug levels and increase side effects; examples include some HIV protease inhibitors and certain antifungals or other strong enzyme blockers, so these combinations are usually avoided or used with great caution.
• UGT1A1 inducers: Medicines that induce UGT1A1 (such as rifampin, some anti‑seizure drugs, and St John’s wort) may lower SN‑38 exposure and could reduce effectiveness, so they are generally avoided.
• Other chemotherapy and myelosuppressive drugs: Combining Trodelvy with other agents that strongly suppress bone marrow increases the risk of severe neutropenia and infection and is typically done only within a clinical trial or carefully designed regimen.
• Other irinotecan/SN‑38–containing products: Trodelvy must not be substituted for or given together with other irinotecan‑based drugs because of overlapping toxicity.
• Because many prescription, over‑the‑counter, and herbal products can affect liver enzymes or bone‑marrow function, patients should have all medicines and supplements reviewed by their oncology team before and during treatment.

Foods, supplements, and alcohol:

• There are no specific food restrictions, but patients are often advised to avoid St John’s wort because of its enzyme‑inducing effects.
• Alcohol does not directly interact with Trodelvy but can worsen nausea, vomiting, dehydration, and liver stress, so limiting or avoiding alcohol is usually recommended during treatment.

Conditions and co‑medications that require extra caution:

• Known reduced UGT1A1 activity (for example, UGT1A1*28 carriers), history of severe neutropenia or diarrhea with irinotecan, or pre‑existing low blood counts increase the risk of serious toxicity.
• Liver disease, especially moderate or severe impairment, may increase drug exposure; such patients often need alternative treatments or very close monitoring.
• Active infections, uncontrolled diarrhea, or poor nutritional status should be addressed before starting therapy whenever possible.
• Live vaccines are generally avoided during treatment with Trodelvy and for a period afterward because of immunosuppression; vaccination plans should be discussed with the oncology team.

Monitoring needs:

• Complete blood counts are usually checked before each dose to guide dosing and to detect neutropenia, anemia, or thrombocytopenia early.
• Periodic blood chemistry tests (including liver and kidney function and electrolytes) help monitor for dehydration from diarrhea and organ‑function changes.
• Pregnancy testing is typically done before starting treatment in people who can become pregnant, and ongoing contraceptive use is reviewed regularly.
• Depending on other medical conditions and medicines, the oncology team may also monitor heart status, weight, and overall performance status to tailor therapy safely.

Q: What is Trodelvy used for?
A: In the United States, Trodelvy is used to treat adults with unresectable locally advanced or metastatic triple‑negative breast cancer or HR‑positive, HER2‑negative metastatic breast cancer who have already received endocrine therapy and multiple prior systemic treatments.

Q: Is Trodelvy chemotherapy or immunotherapy?
A: Trodelvy is an antibody‑drug conjugate, which means it combines a targeted antibody with a chemotherapy payload; it is not classic immunotherapy, but rather a form of targeted chemotherapy delivery.

Q: How long will I stay on Trodelvy?
A: Most people continue Trodelvy in repeating 21‑day cycles as long as scans show the cancer is controlled and side effects remain manageable, with the exact duration decided between you and your oncology team.

Q: When might I notice whether Trodelvy is working?
A: Doctors typically repeat imaging after about 2–3 cycles (roughly 6–9 weeks) to look for tumor shrinkage or stability, though some patients feel symptom improvements such as less pain or better energy before the first scan.

Q: Will I lose my hair on Trodelvy?
A: Hair loss or thinning is very common with Trodelvy, and many patients experience noticeable hair loss during the first few months of treatment, similar to traditional chemotherapy.

Q: Can I work or travel while receiving Trodelvy?
A: Many people are able to work or travel between infusions, but fatigue, low blood counts, and infection risk can limit activity, so plans should be discussed with your oncology team and adjusted based on how you tolerate treatment.